Trial Profile
Incidence and Models of Ticagrelor Discontinuation in Patients With Acute Coronary Syndrome
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions
- Acronyms AD-HOC
- 10 Jan 2023 Status changed from active, no longer recruiting to completed.
- 05 Dec 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 05 Dec 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Mar 2020.